Srikant Datar - Stryker Independent Director
| SYK Stock | USD 390.14 0.00 0.00% |
Director
Dr. Srikant M. Datar, Ph.D., is Independent Director of the Company. Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University since 1996. Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, he was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of Novartis AG, a multinational pharmaceutical and consumer health products company, ICF International, Inc., a management, technology and policy consulting firm, and TMobile US, Inc., a provider of wireless voice, messaging and data services since 2009.
| Age | 68 |
| Tenure | 15 years |
| Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0711 % which means that on every $100 spent on assets, it made $0.0711 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1887 %, implying that it generated $0.1887 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Hagemann | Zimmer Biomet Holdings | 64 | |
| Michael Michelson | Zimmer Biomet Holdings | 69 | |
| Samuel Scott | Abbott Laboratories | 75 | |
| Daniel Starks | Abbott Laboratories | 66 | |
| Angie Risley | Smith Nephew SNATS | 62 | |
| Maria Hilado | Zimmer Biomet Holdings | 56 | |
| Robert Alpern | Abbott Laboratories | 70 | |
| Paul Martin | STERIS plc | 64 | |
| John Ma | Smith Nephew SNATS | 58 | |
| Rick Medlock | Smith Nephew SNATS | 60 | |
| Richard Breeden | STERIS plc | 70 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Elizabeth Nabel | Medtronic PLC | 69 | |
| Nancy McKinstry | Abbott Laboratories | 62 | |
| Katarzyna MazurHofsaess | Smith Nephew SNATS | 57 | |
| Leslie Heisz | Edwards Lifesciences Corp | 60 | |
| Nicholas Valeriani | Edwards Lifesciences Corp | 64 | |
| Phebe Novakovic | Abbott Laboratories | 62 | |
| Arthur Higgins | Zimmer Biomet Holdings | 65 | |
| Randall Hogan | Medtronic PLC | 64 | |
| Richard Steeves | STERIS plc | 58 | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0711 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Silvernail, Independent Director | ||
| Donald Payerle, President Replacement | ||
| Sherilyn McCoy, Independent Director | ||
| Lisa Tatum, Independent Director | ||
| Robert Cohen, CTO Replacement | ||
| Ronda Stryker, Independent Director | ||
| Preston Wells, Vice President - Investor Relations | ||
| Bradford Saar, President Medical | ||
| Spencer Stiles, Group President Orthopaedics and Spine | ||
| Andrew Pierce, Group Neurotechnology | ||
| William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Allan Golston, Lead Independent Director | ||
| Dragana Bunjevac, Middle Europe | ||
| Stuart Silk, Middle Europe | ||
| Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
| Giovanni Caforio, Independent Director | ||
| Jason Beach, Vice Relations | ||
| Roch Doliveux, Independent Director | ||
| Dana McMahon, VP Officer | ||
| Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
| M Fink, Chief Human Resource Officer, Vice President | ||
| Mike Panos, North RD | ||
| Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
| Robert Fletcher, Vice President Chief Legal Officer | ||
| Brian White, President Solutions | ||
| Dylan Crotty, President Instruments | ||
| Brent Ladd, President Endoscopy | ||
| Rajeev Suri, Independent Director | ||
| Alan Douville, Chief VP | ||
| Glenn Boehnlein, Chief Financial Officer, Vice President | ||
| J Pierce, Group President MedSurg and Neurotechnology | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Mary Brainerd, Independent Director | ||
| Srikant Datar, Independent Director | ||
| Maurice BenMayor, President Pacific | ||
| Glenn CPA, VP CFO |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0711 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 157.83 B | ||||
| Shares Outstanding | 381.22 M | ||||
| Shares Owned By Insiders | 5.37 % | ||||
| Shares Owned By Institutions | 80.29 % | ||||
| Number Of Shares Shorted | 4.05 M | ||||
| Price To Earning | 63.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.2 | Dividend Share 3.2 | Earnings Share 9.33 | Revenue Per Share 57.728 | Quarterly Revenue Growth 0.119 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.